TrialLancet (London, England)2019

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.

Donald E Wesson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.